Table 2 Expression of fusion proteins between CPG2(Q)3 and VEGF in COS-7 cells

From: A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs

 

Total CPG2 activity (U well −1 ) in:

Relative CPG2-specific

Relative heparin-binding

Protein

Cells

Medium

activity (%)

activity (%)

CPG2(Q)3-VEGF165

0.0023 (±0.0005)

0.021 (±0.001)

110 (±11)

100

CPG2(Q)3-VEGF109

0.0077 (±0.0005)

0.023 (±0.001)

143 (±13)

2.1

VEGF161-CPG2(Q)3-H6

0.0098 (±0.0013)

0.037 (±0.009)

102 (±13)

99

VEGF115-CPG2(Q)3-H6

0.0009 (±0.0001)

0.066 (±0.011)

140 (±19)

10.2

CPG2(Q)3-H6

0.084 (±0.10)

0.139 (±0.004)

100

2.4

  1. The CPG2 in conditioned media and cell extracts was measured using quantitative Western blotting to estimate the relative protein levels by phosphorimaging. The relative activity of the different fusion proteins could then be estimated using the standard enzyme assay. Quantitative Western blotting was also used to determine the relative efficiency of binding of the fusion proteins to heparin-Sepharose. Data shown for measurements of total activity and relative activity are means (±s.d.) of three transfections.
Back to article page